Risk of Noncervical Anogenital Cancer Up With History of CIN2/3

This article originally appeared here.
Share this content:
Risk of Noncervical Anogenital Cancer Up With History of CIN2/3
Risk of Noncervical Anogenital Cancer Up With History of CIN2/3

WEDNESDAY, July 6, 2016 (HealthDay News) -- Women with a history of cervical intraepithelial neoplasia (CIN)2 or CIN3 have increased risks of subsequent development of anal, vulvar, and vaginal cancers, according to a study published online June 29 in Cancer Epidemiology, Biomarkers & Prevention.

Freja Laerke Sand, from the Danish Cancer Society Research Center in Copenhagen, and colleagues conducted a nationwide cohort study involving 2.8 million women born from 1918 to 1990. Women were followed from the age of 18 years, date of immigration, or January 1978 until emigration; death; Dec. 31, 2012; or date of first diagnosis of anogenital or rectal cancer.

The researchers found that the risks for subsequent anal, vulvar, and vaginal cancer were increased for women with a history of CIN2 or CIN3 compared with those with no such history; the relative risks were higher for CIN3 than for CIN2. There was no indication of excess risk for rectal cancer. In analyses that accounted for the time since first CIN3, the relative risks for anal, vulvar, and vaginal cancers were increased 25 years or longer after CIN3 diagnosis (hazard ratios, 4.8, 3.2, and 5.5, respectively).

"Women with a history of CIN2 or CIN3 have a long-term increased relative risk for developing anal, vulvar, and vaginal cancer due to an impaired ability to control a persistent HPV infection," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

Abstract
Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »


Sign up for myCME e-newsletters


Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

Extended-Release Naltrexone Promising for Opioid Dependence

Extended-Release Naltrexone Promising for Opioid Dependence

Lower use of heroin, other illicit opioids with extended-release naltrexone in superiority analysis

New Expert Consensus Pathway for Mitral Regurgitation

New Expert Consensus Pathway for Mitral Regurgitation

Etiology, mechanism, severity, indications for treatment should be assessed after MR is identified

Many Dermatology Guideline Authors Get Industry Payments

Many Dermatology Guideline Authors Get Industry Payments

22 of 40 guideline authors receiving payments did not accurately disclose industry relationships

is free, fast, and customized just for you!

Already a member?

Sign In Now »